Identification
- Summary
Misoprostol is a prostaglandin E1 analogue used to reduce the risk of NSAID-induced gastric ulcers and to terminate pregnancies.
- Brand Names
- Arthrotec, Cytotec, Mifegymiso
- Generic Name
- Misoprostol
- DrugBank Accession Number
- DB00929
- Background
Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.13,14,4,2,10 The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.3
Misoprostol was granted FDA approval on 27 December 1988.13
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Misoprostol (DB00929)
- Weight
- Average: 382.5341
Monoisotopic: 382.271924326 - Chemical Formula
- C22H38O5
- Synonyms
- Misoprostol
- Misoprostolum
Pharmacology
- Indication
Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients.13 Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers.14 Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.4,2,10
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Prophylaxis of Gastric ulcer •••••••••••• Treatment of Incomplete abortion ••• ••••• Treatment of Missed abortion ••• ••••• Treatment of Postpartum hemorrhage ••• ••••• Prophylaxis of Postpartum hemorrhage ••• ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Misoprostol is a prostaglandin E1 analog used to reduce the risk of NSAID induced gastric ulcers by reducing secretion of gastric acid from parietal cells.3,13,14 Misoprostol is also used to manage miscarriages and used alone or in combination with mifepristone for first trimester abortions.4,2,6 An oral dose of misoprostol has an 8 minute onset of action and a duration of action of approximately 2 hours, a sublingual dose has an 11 minute onset of action and a duration of action of approximately 3 hours, a vaginal dose has a 20 minute onset of action and a duration of action of approximately 4 hours, and a rectal dose has a 100 minute onset of action and a duration of action of approximately 4 hours.7
- Mechanism of action
Misoprostol is a synthetic prostaglandin E1 analog that stimulates prostaglandin E1 receptors on parietal cells in the stomach to reduce gastric acid secretion.3 Mucus and bicarbonate secretion are also increased along with thickening of the mucosal bilayer so the mucosa can generate new cells.3
Misoprostol binds to smooth muscle cells in the uterine lining to increase the strength and frequency of contractions as well as degrade collagen and reduce cervical tone.3
Target Actions Organism AProstaglandin E2 receptor EP3 subtype agonistHumans AProstaglandin E2 receptor EP2 subtype agonistHumans AProstaglandin E2 receptor EP1 subtype agonistHumans UProstaglandin E2 receptor EP4 subtype agonistHumans - Absorption
For an 800µg oral dose of misoprostol, the AUC was 2.0192±0.8032h*ng/mL, the Cmax was 2.6830±1.2161ng/mL, and a tmax of 0.345±0.186h.5 For a 800µg sublingual dose of misoprostol, the AUC was 3.2094±1.0417h*ng/mL, the Cmax was 2.4391±1.1567ng/mL, and a tmax of 0.712±0.415h.5 For a 800µg buccal dose of misoprostol, the AUC was 2.0726±0.3578h*ng/mL, the Cmax was 1.3611±0.3436ng/mL, and a tmax of 1.308±0.624h.5
- Volume of distribution
Data regarding the volume of distribution of misoprostol is scarce.
The apparent volume of distribution of the active metabolite of misoprostol was in subjects with normal renal function was 13.6±8.0L/kg, with mild renal impairment was 17.3±23.0L/kg, with moderate renal impairment was 14.3±6.8L/kg, and with end stage renal disease was 11.0±9.6L/kg.8
- Protein binding
Misoprostol is <90% protein bound in serum.13,14 Its active metabolite, misoprostol acid, is 81-89% protein bound in serum.9
- Metabolism
Misoprostol is de-esterified to its active metabolite, misoprostol acid, also known as SC-30695.1 This metabolite is further reduced to dinor and tetranor metabolites (SC-41411), a prostaglandin F1 (PGF1) analog of SC-41411, and a ω-16-carboxylic acid derivative.1 However, the majority of these metabolites are not well described in the literature.1
Hover over products below to view reaction partners
- Route of elimination
As much as 73.2±4.6% of a radiolabelled oral dose of misoprostol is recovered in the urine.1,14
- Half-life
The half life of an 800µg oral dose is 1.0401±0.5090h, for a sublingual dose is 0.8542±0.1170h, and for a buccal dose is 0.8365±0.1346h.5
- Clearance
Because of the rapid de-esterification of misoprostol before or during absorption, it is usually undetectable in plasma.8 Misoprostol's active metabolite, misoprostol acid, has a total body clearance of 0.286L/kg/min.8 Subjects with mild renal impairment had a total body clearance of 0.226±0.073L/kg/min, subjects with moderate renal impairment had a total body clearance of 0.270±0.103L/kg/min, and subjects with end stage renal disease had a total body clearance of 0.105±0.052L/kg/min.8
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
The oral LD50 in rats is 81mg/kg and in mice is 27mg/kg.12 The intraperitoneal LD50 in rats is 40mg/kg and in mice is 70mg/kg.12
Patients experiencing an overdose may present with sedation, tremor, convulsions, dyspnea, abdominal pain, diarrhea, fever, palpitations, hypotension, and bradycardia.11,13,14 Hemodialysis is not expected to be useful in the treatment of misoprostol overdose13 but oral activated charcoal may help reduce absorption.14 In the event of an overdose, treat symptoms with supportive therapy.13 This may include removal of undissolved tablets from the vagina or buccal cavity, intravenous fluid replacement, acetaminophen, diazepam, haloperidol, or intramuscular diclofenac depending on the symptoms that present.11
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareCarbetocin The risk or severity of adverse effects can be increased when Misoprostol is combined with Carbetocin. Carboprost tromethamine Carboprost tromethamine may increase the uterotonic activities of Misoprostol. Hydrotalcite The risk or severity of adverse effects can be increased when Hydrotalcite is combined with Misoprostol. Magaldrate The risk or severity of adverse effects can be increased when Magaldrate is combined with Misoprostol. Magnesium The risk or severity of adverse effects can be increased when Magnesium is combined with Misoprostol. - Food Interactions
- Take with food. Food decreases incidence of diarrhea.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Images
- International/Other Brands
- Isprelor
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Cytotec Tablet 100 ug/1 Oral Cardinal Health 1988-12-27 2015-12-31 US 
Cytotec Tablet 200 ug/1 Oral Pfizer Laboratories Div Pfizer Inc 1986-12-27 Not applicable US Cytotec Tablet 200 ug/1 Oral Apotheca, Inc. 2010-01-01 Not applicable US Cytotec Tablet 200 ug/1 Oral A S Medication Solutions 1986-12-27 Not applicable US Cytotec Tablet 100 ug/1 Oral Pfizer Laboratories Div Pfizer Inc 1986-12-27 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Misoprostol Tablet 100 ug/1 Oral Cadila Healthcare Limited 2020-01-14 Not applicable US Misoprostol Tablet 100 ug/1 Oral Novel Laboratories, Inc. 2012-07-25 Not applicable US Misoprostol Tablet 100 ug/1 Oral Aidarex Pharmaceuticals LLC 2012-07-25 Not applicable US 
Misoprostol Tablet 100 ug/1 Oral Apotheca, Inc. 2010-02-25 2010-04-15 US Misoprostol Tablet 200 ug/1 Oral Micro Labs Limited 2023-01-01 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Act Diclo-miso Misoprostol (200 mcg) + Diclofenac sodium (75 mg) Tablet, delayed release Oral Actavis Pharma Company 2013-03-27 2019-08-08 Canada 
Act Diclo-miso Misoprostol (200 mcg) + Diclofenac sodium (50 mg) Tablet, delayed release Oral Actavis Pharma Company 2013-03-27 2019-08-08 Canada Arthrotec Misoprostol (200 ug/1) + Diclofenac sodium (50 mg/1) Tablet, film coated Oral Pfizer Laboratories Div Pfizer Inc 1997-12-24 Not applicable US 
Arthrotec Misoprostol (200 ug/1) + Diclofenac sodium (50 mg/1) Tablet, film coated Oral PD-Rx Pharmaceuticals, Inc. 1997-12-24 2019-09-12 US Arthrotec Misoprostol (200 ug/1) + Diclofenac sodium (75 mg/1) Tablet, film coated Oral Pfizer Laboratories Div Pfizer Inc 1997-12-24 Not applicable US 
Categories
- ATC Codes
- G02AD06 — Misoprostol
- G02AD — Prostaglandins
- G02A — UTEROTONICS
- G02 — OTHER GYNECOLOGICALS
- G — GENITO URINARY SYSTEM AND SEX HORMONES
- A02BB — Prostaglandins
- A02B — DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- A02 — DRUGS FOR ACID RELATED DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Abortifacient Agents
- Abortifacient Agents, Nonsteroidal
- Alimentary Tract and Metabolism
- Anti-Ulcer Agents
- Antiinflammatory and Antirheumatic Products
- Antiinflammatory and Antirheumatic Products, Non-Steroids
- Autacoids
- Biological Factors
- Drugs causing inadvertant photosensitivity
- Drugs for Acid Related Disorders
- Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
- Eicosanoids
- Fatty Acids
- Fatty Acids, Unsaturated
- Gastrointestinal Agents
- Genito Urinary System and Sex Hormones
- Inflammation Mediators
- Lipids
- Musculo-Skeletal System
- Photosensitizing Agents
- Propionates
- Prostaglandin E1 Analog
- Prostaglandins
- Prostaglandins E, Synthetic
- Prostaglandins, Synthetic
- Reproductive Control Agents
- Uterotonic agents
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Fatty Acyls
- Sub Class
- Eicosanoids
- Direct Parent
- Prostaglandins and related compounds
- Alternative Parents
- Fatty acid methyl esters / Cyclopentanols / Tertiary alcohols / Methyl esters / Cyclic ketones / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Organic oxides / Hydrocarbon derivatives
- Substituents
- Alcohol / Aliphatic homomonocyclic compound / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Cyclic alcohol / Cyclic ketone / Cyclopentanol / Fatty acid ester / Fatty acid methyl ester
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 0E43V0BB57
- CAS number
- 59122-46-2
- InChI Key
- OJLOPKGSLYJEMD-URPKTTJQSA-N
- InChI
- InChI=1S/C22H38O5/c1-4-5-14-22(2,26)15-10-12-18-17(19(23)16-20(18)24)11-8-6-7-9-13-21(25)27-3/h10,12,17-18,20,24,26H,4-9,11,13-16H2,1-3H3/b12-10+/t17-,18-,20-,22?/m1/s1
- IUPAC Name
- methyl 7-[(1R,2R,3R)-3-hydroxy-2-[(1E)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate
- SMILES
- CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
References
- Synthesis Reference
Salah Ahmed, Raj Mahajan, "Vaginal tablets comprising misoprostol and methods of making and using the same." U.S. Patent US20070071814, issued March 29, 2007.
US20070071814- General References
- Schoenhard G, Oppermann J, Kohn FE: Metabolism and pharmacokinetic studies of misoprostol. Dig Dis Sci. 1985 Nov;30(11 Suppl):126S-128S. doi: 10.1007/bf01309397. [Article]
- Turner JV, Agatonovic-Kustrn S, Ward H: Off-label use of misoprostol in gynaecology. Facts Views Vis Obgyn. 2015 Dec 28;7(4):261-264. [Article]
- Krugh M, Maani CV: Misoprostol . [Article]
- Speer L: Misoprostol Alone is Associated with High Rate of Successful First-Trimester Abortion. Am Fam Physician. 2019 Jul 15;100(2):119. [Article]
- Frye LJ, Byrne ME, Winikoff B: A crossover pharmacokinetic study of misoprostol by the oral, sublingual and buccal routes. Eur J Contracept Reprod Health Care. 2016 Aug;21(4):265-8. doi: 10.3109/13625187.2016.1168799. Epub 2016 Apr 22. [Article]
- Fjerstad M, Trussell J, Sivin I, Lichtenberg ES, Cullins V: Rates of serious infection after changes in regimens for medical abortion. N Engl J Med. 2009 Jul 9;361(2):145-51. doi: 10.1056/NEJMoa0809146. [Article]
- Tang OS, Gemzell-Danielsson K, Ho PC: Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007 Dec;99 Suppl 2:S160-7. doi: 10.1016/j.ijgo.2007.09.004. Epub 2007 Oct 26. [Article]
- Foote EF, Lee DR, Karim A, Keane WF, Halstenson CE: Disposition of misoprostol and its active metabolite in patients with normal and impaired renal function. J Clin Pharmacol. 1995 Apr;35(4):384-9. [Article]
- Cook CS, Schoenhard GL, Karim A: Effect of salicylic acid on the plasma protein binding and pharmacokinetics of misoprostol acid. J Pharm Sci. 1994 Jun;83(6):883-6. doi: 10.1002/jps.2600830625. [Article]
- Hobday K, Hulme J, Homer C, Zualo Wate P, Belton S, Prata N: "My job is to get pregnant women to the hospital": a qualitative study of the role of traditional birth attendants in the distribution of misoprostol to prevent post-partum haemorrhage in two provinces in Mozambique. Reprod Health. 2018 Oct 16;15(1):174. doi: 10.1186/s12978-018-0622-4. [Article]
- Barros JG, Reis I, Graca LM: Acute misoprostol toxicity during the first trimester of pregnancy. Int J Gynaecol Obstet. 2011 May;113(2):157-8. doi: 10.1016/j.ijgo.2010.12.006. Epub 2011 Feb 22. [Article]
- Cayman Chemicals: Misoprostol MSDS [Link]
- FDA Approved Drug Products: Misoprostol Tablets [Link]
- FDA Approved Drug Products: Misoprostol and Diclofenac Tablets [Link]
- External Links
- Human Metabolome Database
- HMDB0015064
- KEGG Drug
- D00419
- PubChem Compound
- 5282381
- PubChem Substance
- 46505041
- ChemSpider
- 4445541
- BindingDB
- 85606
- 42331
- ChEBI
- 63610
- ChEMBL
- CHEMBL606
- Therapeutic Targets Database
- DAP000358
- PharmGKB
- PA450523
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Misoprostol
- FDA label
- Download (246 KB)
- MSDS
- Download (147 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count 4 Active Not Recruiting Treatment Induction of Labour 1 4 Completed Health Services Research Abortion, Therapeutic 1 4 Completed Health Services Research Menstrual Regulation 1 4 Completed Other Contraceptive Device; Complications 1 4 Completed Prevention Bleeding During Myomectomy 1
Pharmacoeconomics
- Manufacturers
- Gd searle llc
- Ivax pharmaceuticals inc sub teva pharmaceuticals usa
- Packagers
- Apotheca Inc.
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Cardinal Health
- Chirogate International Inc.
- Direct Dispensing Inc.
- DispenseXpress Inc.
- Dispensing Solutions
- GD Searle LLC
- Greenstone LLC
- H.J. Harkins Co. Inc.
- Hawkins Inc.
- Innoviant Pharmacy Inc.
- Ivax Pharmaceuticals
- Lake Erie Medical and Surgical Supply
- Murfreesboro Pharmaceutical Nursing Supply
- Neuman Distributors Inc.
- Nucare Pharmaceuticals Inc.
- PD-Rx Pharmaceuticals Inc.
- Pfizer Inc.
- Pharmacia Inc.
- Physicians Total Care Inc.
- Piramal Healthcare
- Rebel Distributors Corp.
- Southwood Pharmaceuticals
- Dosage Forms
Form Route Strength Tablet 25 MICROGRAMMI Tablet Oral 200.000 µg Tablet, film coated Oral Tablet, coated Oral Tablet Oral Tablet Oral 0.200 mg Tablet Vaginal 25 mcg Tablet Vaginal 20000000 mg Tablet Vaginal 50 cg Tablet, orally disintegrating Oral 400 mcg Tablet Oral 100 ug/1 Tablet Oral 200 ug/1 Tablet Oral 400 MCG Tablet Oral 200 mcg Tablet Oral 200 cg Tablet, delayed release Oral Tablet Oral Tablet Vaginal 200 mcg Tablet 200 mg Tablet Oral 20.000 mg Tablet Kit; tablet Buccal; Oral Tablet 400 MICROGRAMMI Tablet Oral 100 mcg Kit; tablet; tablet, orally disintegrating Oral Drug delivery system Vaginal 200 mcg Tablet Oral 200.000 mcg Tablet Tablet 200 mcg - Prices
Unit description Cost Unit Misoprostol hpmc powder 152.0USD g Cytotec 60 200 mcg tablet Bottle 121.93USD bottle Cytotec 60 100 mcg tablet Bottle 81.36USD bottle Arthrotec 75 tablet ec 4.07USD tablet Arthrotec ec 50 mg-200 mcg tablet 2.99USD tablet Arthrotec ec 75 mg-200 mcg tablet 2.99USD tablet Arthrotec ec 75 tablet 2.96USD tablet Arthrotec 75 75-200 mg-mcg tablet 2.82USD tablet Arthrotec 50 50-200 mg-mcg tablet 2.7USD tablet Cytotec 200 mcg tablet 1.95USD tablet Cytotec 100 mcg tablet 1.34USD tablet Misoprostol 200 mcg tablet 1.22USD tablet Misoprostol 100 mcg tablet 0.84USD tablet Apo-Misoprostol 200 mcg Tablet 0.45USD tablet Apo-Misoprostol 100 mcg Tablet 0.27USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US5601843 No 1997-02-11 2014-02-11 US US5698225 No 1997-12-16 2010-05-03 US
Properties
- State
- Liquid
- Experimental Properties
Property Value Source melting point (°C) 261-263 http://www.chemspider.com/Chemical-Structure.4445541.html water solubility 1.6mg/mL https://www.caymanchem.com/pdfs/13820.pdf - Predicted Properties
Property Value Source Water Solubility 0.0164 mg/mL ALOGPS logP 3.88 ALOGPS logP 3.86 Chemaxon logS -4.4 ALOGPS pKa (Strongest Acidic) 14.69 Chemaxon pKa (Strongest Basic) -0.95 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 83.83 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 107.88 m3·mol-1 Chemaxon Polarizability 45.44 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9157 Blood Brain Barrier + 0.938 Caco-2 permeable - 0.5339 P-glycoprotein substrate Substrate 0.6607 P-glycoprotein inhibitor I Non-inhibitor 0.7261 P-glycoprotein inhibitor II Inhibitor 0.6504 Renal organic cation transporter Non-inhibitor 0.9146 CYP450 2C9 substrate Non-substrate 0.857 CYP450 2D6 substrate Non-substrate 0.9024 CYP450 3A4 substrate Substrate 0.6281 CYP450 1A2 substrate Non-inhibitor 0.8358 CYP450 2C9 inhibitor Non-inhibitor 0.8175 CYP450 2D6 inhibitor Non-inhibitor 0.9459 CYP450 2C19 inhibitor Non-inhibitor 0.8199 CYP450 3A4 inhibitor Non-inhibitor 0.795 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9591 Ames test Non AMES toxic 0.8289 Carcinogenicity Non-carcinogens 0.8941 Biodegradation Not ready biodegradable 0.8797 Rat acute toxicity 3.7051 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.964 hERG inhibition (predictor II) Non-inhibitor 0.8734
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS splash10-0zgl-7669000000-5ba5f8c705e7fe123902 Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0002-0029000000-f3907635f7331ff3eb6d Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-03e9-0009000000-7a97814b180ef54d1e90 Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-001j-0019000000-2547611a647bfe53f4ce Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-052b-4696000000-e0130b98821e7e20c1be Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-0zi0-6279000000-dc8948fc7abb81fa3f3a Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-0pe9-2910000000-cdd65ac8b750de4866e2 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 212.8705905 predictedDarkChem Lite v0.1.0 [M-H]- 227.9700905 predictedDarkChem Lite v0.1.0 [M-H]- 207.58379 predictedDeepCCS 1.0 (2019) [M+H]+ 214.5217905 predictedDarkChem Lite v0.1.0 [M+H]+ 230.7699905 predictedDarkChem Lite v0.1.0 [M+H]+ 209.942 predictedDeepCCS 1.0 (2019) [M+Na]+ 212.1805905 predictedDarkChem Lite v0.1.0 [M+Na]+ 216.19978 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Rna polymerase ii transcription factor activity, ligand-activated sequence-specific dna binding
- Specific Function
- Receptor for prostaglandin E2 (PGE2); the EP3 receptor may be involved in inhibition of gastric acid secretion, modulation of neurotransmitter release in central and peripheral neurons, inhibition ...
- Gene Name
- PTGER3
- Uniprot ID
- P43115
- Uniprot Name
- Prostaglandin E2 receptor EP3 subtype
- Molecular Weight
- 43309.335 Da
References
- Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [Article]
- Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [Article]
- Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [Article]
- Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [Article]
- Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Prostaglandin e receptor activity
- Specific Function
- Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. The subsequent raise in intracellular cAMP is responsible for the ...
- Gene Name
- PTGER2
- Uniprot ID
- P43116
- Uniprot Name
- Prostaglandin E2 receptor EP2 subtype
- Molecular Weight
- 39759.945 Da
References
- Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [Article]
- Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [Article]
- Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [Article]
- Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [Article]
- Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Prostaglandin e receptor activity
- Specific Function
- Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an importa...
- Gene Name
- PTGER1
- Uniprot ID
- P34995
- Uniprot Name
- Prostaglandin E2 receptor EP1 subtype
- Molecular Weight
- 41800.655 Da
References
- Krugh M, Maani CV: Misoprostol . [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Prostaglandin e receptor activity
- Specific Function
- Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(s) proteins that stimulate adenylate cyclase. Has a relaxing effect on smooth muscle. May play an important role...
- Gene Name
- PTGER4
- Uniprot ID
- P35408
- Uniprot Name
- Prostaglandin E2 receptor EP4 subtype
- Molecular Weight
- 53118.845 Da
References
- Nakae K, Hayashi F, Hayashi M, Yamamoto N, Iino T, Yoshikawa S, Gupta J: Functional role of prostacyclin receptor in rat dorsal root ganglion neurons. Neurosci Lett. 2005 Nov 18;388(3):132-7. [Article]
- Li J, Liang X, Wang Q, Breyer RM, McCullough L, Andreasson K: Misoprostol, an anti-ulcer agent and PGE2 receptor agonist, protects against cerebral ischemia. Neurosci Lett. 2008 Jun 20;438(2):210-5. doi: 10.1016/j.neulet.2008.04.054. Epub 2008 Apr 20. [Article]
- Guan Y, Stillman BA, Zhang Y, Schneider A, Saito O, Davis LS, Redha R, Breyer RM, Breyer MD: Cloning and expression of the rabbit prostaglandin EP2 receptor. BMC Pharmacol. 2002 Jun 27;2:14. [Article]
- Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. [Article]
- Nataraj C, Thomas DW, Tilley SL, Nguyen MT, Mannon R, Koller BH, Coffman TM: Receptors for prostaglandin E(2) that regulate cellular immune responses in the mouse. J Clin Invest. 2001 Oct;108(8):1229-35. [Article]
- Crider JY, Xu SX, Sharif NA: Pharmacology of functional endogenous IP prostanoid receptors in NCB-20 cells: comparison with binding data from human platelets. Prostaglandins Leukot Essent Fatty Acids. 2001 Nov-Dec;65(5-6):253-8. [Article]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:55